Earnings History Data for Lineage Cell Therapeutics, Inc. (LCTX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are in clinical stage. Lineage Cell Therapeutics Inc., formerly known as BioTime Inc., is based in Carlsbad, California.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
14-11-2024	AH		LCTX	Lineage Cell Therapeutics, Inc.	179.17	-0.02	-0.04	-0.04	Lineage Cell Therapeutics GAAP EPS of -$0.02 beats by $0.02, revenue of $3.77M beats by $2.88M [11/14/2024 4:04 PM]	0.8622	-0.02 (-2.58%)	0.90	0.02 (1.98%)	0.77 - 1.61	802,303	480,000	2,892
Lineage Cell Therapeutics GAAP EPS of -$0.02 beats by $0.02, revenue of $3.77M beats by $2.88M [11/14/2024 4:04 PM] Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [2024-11-14 04:01PM]
08-08-2024	AH		LCTX	Lineage Cell Therapeutics, Inc.	171.79	-0.03	-0.04	-0.03	Lineage Cell Therapeutics GAAP EPS of -$0.03 beats by $0.01, revenue of $1.4M beats by $0.61M [8/8/2024 4:10 PM]	0.9014	0.02 (2.36%)	0.92	0.04 (4.49%)	0.84 - 1.61	277,565	650,000	27,835
Lineage Cell Therapeutics GAAP EPS of -$0.03 beats by $0.01, revenue of $1.4M beats by $0.61M [8/8/2024 4:10 PM]
09-05-2024	AH		LCTX	Lineage Cell Therapeutics, Inc.	237.55	-0.04	-0.04	-0.03	Lineage Cell Therapeutics GAAP EPS of -$0.04 in-line, revenue of $1.44M beats by $0.08M [5/9/2024 4:22 PM]	1.17	-0.01 (-0.85%)	1.21	0.03 (2.54%)	0.84 - 1.61	453,848	1,150,000	293
Lineage Cell Therapeutics GAAP EPS of -$0.04 in-line, revenue of $1.44M beats by $0.08M [5/9/2024 4:22 PM]
07-03-2024	AH		LCTX	Lineage Cell Therapeutics, Inc.	188.99	-0.03	-0.07	-0.03	Lineage Cell Therapeutics GAAP EPS of -$0.03 in-line, revenue of $2.1M misses by $0.74M [3/7/2024 4:09 PM]	1.30	0.17 (15.04%)	1.14	0.01 (0.88%)	0.84 - 1.57	2,898,474	460,000	3,681
Lineage Cell Therapeutics GAAP EPS of -$0.03 in-line, revenue of $2.1M misses by $0.74M [3/7/2024 4:09 PM]
09-11-2023	AH		LCTX	Lineage Cell Therapeutics, Inc.	197.73	-0.04	-0.04	-0.04	Lineage Cell Therapeutics GAAP EPS of -$0.04 in-line, revenue of $1.25M misses by $1.33M [11/9/2023 4:05 PM]	1.04	-0.03 (-2.80%)	1.06	-0.01 (-0.93%)	1.00 - 1.58	667,299	390,000	13,655
Lineage Cell Therapeutics GAAP EPS of -$0.04 in-line, revenue of $1.25M misses by $1.33M [11/9/2023 4:05 PM]
10-08-2023	AH		LCTX	Lineage Cell Therapeutics, Inc.	241.65	-0.03	-0.04	-0.04	Lineage Cell Therapeutics GAAP EPS of -$0.03 beats by $0.01, revenue of $3.23M beats by $1.04M [8/10/2023 4:37 PM]	1.43	0.02 (1.42%)	1.50	0.09 (6.38%)	1.02 - 1.64	363,357	460,000	5,937
Lineage Cell Therapeutics GAAP EPS of -$0.03 beats by $0.01, revenue of $3.23M beats by $1.04M [8/10/2023 4:37 PM]
11-05-2023	AH	4:05 PM ET (May 11)	LCTX	Lineage Cell Therapeutics, Inc.	220.47	-0.03	-0.03	-0.04	Lineage Cell Therapeutics GAAP EPS of -$0.03 beats by $0.01, revenue of $2.39M beats by $0.38M [5/11/2023 4:51 PM]	1.38	-0.03 (-2.13%)	1.46	0.05 (3.55%)	1.02 - 1.79	228,950	320,000	699
Lineage Cell Therapeutics GAAP EPS of -$0.03 beats by $0.01, revenue of $2.39M beats by $0.38M [5/11/2023 4:51 PM]
09-03-2023	AH	4:05 PM ET (Mar 9)	LCTX	Lineage Cell Therapeutics, Inc.	190.48	-0.03	-0.03	-0.05	Lineage Cell Therapeutics GAAP EPS of -$0.15 in-line, revenue of $14.7M misses by $0.63M [3/9/2023 4:03 PM]	1.44	-0.02 (-1.71%)	1.45	-0.01 (-0.68%)	1.02 - 1.79	652,167	310,000	53,267
Lineage Cell Therapeutics GAAP EPS of -$0.15 in-line, revenue of $14.7M misses by $0.63M [3/9/2023 4:03 PM]
10-11-2022	AH	4:05 PM ET (Nov 10)	LCTX	Lineage Cell Therapeutics, Inc.	191.98	-0.04	-0.03	-0.05	Lineage Cell Therapeutics GAAP EPS of -$0.04, revenue of $3M [11/10/2022 4:06 PM]	1.42	0.09 (6.77%)	1.27	-0.06 (-4.51%)	1.02 - 2.71	418,687	320,000	100
Lineage Cell Therapeutics GAAP EPS of -$0.04, revenue of $3M [11/10/2022 4:06 PM] Lineage Cell (LCTX) Reports Q3 Loss, Misses Revenue Estimates [Nov-10-22 06:35PM] Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update [Nov-10-22 04:05PM]
11-08-2022	AH	4:05 PM ET (Aug 11)	LCTX	Lineage Cell Therapeutics, Inc.	238.47	-0.04	-0.03	-0.03	Lineage Cell Therapeutics GAAP EPS of -$0.04, revenue of $4.6M [8/11/2022 4:08 PM]	1.57	0.02 (1.29%)	1.60	0.05 (3.23%)	1.10 - 2.80	194,945	580,000	2,001
Lineage Cell Therapeutics GAAP EPS of -$0.04, revenue of $4.6M [8/11/2022 4:08 PM]
12-05-2022	AH	4:05 PM ET (May 12)	LCTX	Lineage Cell Therapeutics, Inc.	193.48	-0.04	0.01	-0.06	Lineage Cell Therapeutics GAAP EPS of -$0.04 misses by $0.02, revenue of $5.24M misses by $3.66M [5/12/2022 4:13 PM]	1.13	-0.05 (-4.24%)	1.23	0.05 (4.24%)	1.10 - 3.00	680,234	750,000	301
Lineage Cell Therapeutics GAAP EPS of -$0.04 misses by $0.02, revenue of $5.24M misses by $3.66M [5/12/2022 4:13 PM] BioCardia, Inc. (BCDA) Reports Q1 Loss, Lags Revenue Estimates [May-11-22 05:55PM] Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update [May-12-22 04:05PM] Lineage Cell (LCTX) Reports Q1 Loss, Misses Revenue Estimates [May-12-22 06:05PM]
10-03-2022	AH	4:05 PM ET (Mar 10)	LCTX	Lineage Cell Therapeutics, Inc.	196.48	-0.05	-0.05	0.01	Lineage Cell Therapeutics GAAP EPS of -$0.17 misses by $0.12, revenue of $1.2M beats by $0.56M [3/10/2022 4:14 PM]	1.35	-0.05 (-3.57%)	1.39	-0.01 (-0.71%)	1.25 - 3.00	638,159	480,000	900
Lineage Cell Therapeutics GAAP EPS of -$0.17 misses by $0.12, revenue of $1.2M beats by $0.56M [3/10/2022 4:14 PM] Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update [Mar-10-22 04:05PM] Lineage Cell (LCTX) Reports Q4 Loss [Mar-10-22 06:25PM]
10-11-2021	AH	4:05 PM ET (Nov 10)	LCTX	Lineage Cell Therapeutics, Inc.	380.95	-0.05	-0.05	-0.04	Lineage Cell Therapeutics EPS in-line, beats on revenue [11/10/2021 4:15 PM]	2.49	0.13 (5.51%)	2.39	0.03 (1.27%)	1.25 - 3.13	292,774	640,000	14,229
Lineage Cell Therapeutics EPS in-line, beats on revenue [11/10/2021 4:15 PM] Lineage Reports Third Quarter 2021 Financial Results and Highlights Progress From Clinical Cell Therapy Programs [Nov-10-21 04:05PM] Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates [Nov-10-21 06:45PM]
12-08-2021	AH	4:05 PM ET (Aug 12)	LCTX	Lineage Cell Therapeutics, Inc.	385.45	-0.03	-0.03	-0.04		2.61	0.0 (0.00%)	2.57	-0.04 (-1.53%)	0.82 - 3.13	376,330	400,000	6,834
Age-Related Macular Degeneration: What is Dry AMD, and How is Lineage Cell Therapeutics Changing the Game? [Aug-11-21 04:25PM] Lineage Reports Second Quarter 2021 Financial Results and Highlights Additional Progress From Clinical Cell Therapy Programs [Aug-12-21 04:05PM] Lineage Cell (LCTX) Reports Q2 Loss, Misses Revenue Estimates [Aug-12-21 06:25PM] Lineage Cell Therapeutics, Inc. (LCTX) Q2 2021 Earnings Call Transcript [Aug-13-21 02:30AM]
13-05-2021	AH	4:05 PM ET (May 13)	LCTX	Lineage Cell Therapeutics, Inc.	361.46	-0.06	-0.04	-0.06	Lineage Cell Therapeutics EPS beats by $0.03, misses on revenue [5/13/2021 4:10 PM]	2.27	0.10 (4.38%)	2.26	0.09 (4.15%)	0.73 - 3.13	713,499	1,190,000	878
Lineage Cell Therapeutics EPS beats by $0.03, misses on revenue [5/13/2021 4:10 PM] Lineage Cell Therapeutics, Inc. to Host Earnings Call [May-13-21 02:30PM] Lineage Reports First Quarter 2021 Financial Results and Highlights Significant Progress With All Three Clinical Programs [May-13-21 04:05PM] Lineage Cell (LCTX) Reports Q1 Loss, Misses Revenue Estimates [May-13-21 07:20PM] Lineage Cell Therapeutics, Inc. (LCTX) Q1 2021 Earnings Call Transcript [May-14-21 03:01AM] Lineage Cell Delivers Lower-than-Feared Q1 Loss; Shares Pop 5% [May-14-21 08:52AM]
11-03-2021	AH	4:05 PM ET (Mar 11)	LCTX	Lineage Cell Therapeutics, Inc.	265.47	0.01	-0.05	-0.03	Lineage Cell Therapeutics EPS beats by $0.03, misses on revenue [3/11/2021 4:09 PM]	2.50	0.16 (6.92%)	2.43	0.09 (3.85%)	0.58 - 3.13	2,398,588	1,880,525	28,439
Lineage Cell Therapeutics EPS beats by $0.03, misses on revenue [3/11/2021 4:09 PM] Lineage Cell Therapeutics, Inc. to Host Earnings Call [Mar-11-21 02:30PM] Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update [Mar-11-21 04:05PM] Lineage Cell (LCTX) Tops Q4 Earnings Estimates [Mar-11-21 05:45PM] Lineage Cell Therapeutics, Inc. (LCTX) Q4 2020 Earnings Call Transcript [Mar-12-21 03:00AM]
04-11-2020	AH	4:05 PM ET (Nov 4)	LCTX	Lineage Cell Therapeutics, Inc.	172.48	-0.04	-0.04	-0.04	Lineage Cell Therapeutics EPS misses by $0.01, beats on revenue [11/4/2020 4:28 PM]	1.32	0.11 (9.09%)	1.25	0.04 (3.31%)	0.53 - 1.67	834,907	531,362	3,352

06-08-2020	AH		LCTX	Lineage Cell Therapeutics, Inc.	127.35	-0.04	-0.04	-0.06	Lineage Cell Therapeutics EPS in-line, misses on revenue [8/6/2020 4:21 PM]	0.9237	0.03 (0.40%)	0.95	0.03 (3.26%)	0.53 - 1.67	364,017	642,863	26,470